«AbbVie's Lutikizumab Succeeds in Late-Stage Trial for Hidradenitis Suppurativa, But Falls » — τι περιλαμβάνει αυτή η σελίδα του δικτύου. AbbVie's investigational drug lutikizumab met its primary goal in a Phase 3 trial for hidradenitis suppurativa, a chronic inflammatory skin condition, but the magnitude of benefit disappointed investors and analysts. The trial demonstrated a statistically significant improvement in disease severity compared to placebo, yet the results were more modest than anticipated, raising questions about the drug's commercial potential in a competitive market. Lutikizumab, an IL-1α/β inhibitor, is part of AbbVie's strategy to expand its immunology portfolio beyond its blockbuster Humira, which faces biosimilar competition.
The company had hoped lutikizumab would become a new growth driver, but the data suggest it may face challenges differentiating from existing therapies like adalimumab and secukinumab. Analysts noted that while the drug works, its efficacy may not be compelling enough to capture significant market share without additional advantages in safety or convenience. Το πλήρες περιεχόμενο παραμένει στην αρχική σελίδα, στην οποία οδηγεί αυτή η καταχώριση.